IDP Pharma

The Company

IDP Pharma is a clinical stage biotechnological company that develops therapies to treat incurable cancers. The company is exclusively focused on developing first time ever drugs directly targeting a fundamental class of disease drivers, intrinsically disordered proteins (IDPs), thanks to its novel intrametics^TM platform.

The companys' most advanced asset, IDP-121, is the first drug that addresses the underlaying cause of multiple myeloma, an incurable cancer. The current financing round will allow progression of IDP-121 in Phase I/II clinical trials in multiple myeloma patients, reaching a licensing agreement or company acquisition deal with a top pharmaceutical company.

The driving force

In 2015, Drs Laura Nevola and Santiago Esteban founded IDP Pharma to break through the emerging field of intrinsically disordered proteins (IDPs), key players in human disease that remain out of reach to the pharmaceutical industry. The founders bring two decades decoding the mysteries of IDP proteins, recognised by the scientific community in the late 90´s. Today, IDP Pharma has become a clinical stage company leading the development of therapies directed to IDPs, disbelieved for long and now named to become one of the next revolutions.

The opportunity: IDPs, "the invisible proteins"

Intrinsically Disordered Proteins (IDPs) represent half of the human proteins, perform a plethora of cellular functions and play key roles in human disease, including cancer, respiratory and metabolic diseases, neurological disorders, and skin disorders.

Due to their extreme flexibility the structure of IDPs can not be determined and, as a result, IDPs remain as ¨invisible targets¨. This contrasts with classical, rigid proteins, such as enzymes, targeted by the pharmaceutical industry.

Lack of technologies to design drugs for these "invisible proteins" leave many medical opportunities unrealized, resulting in lack of therapies or partially effective treatments.

Our solution: Intrametics^TM

Thanks to a whole new concept, IDP Pharma´s Intrametics^TM proprietary technology enables for the first-time the direct inhibition and cellular degradation of IDPs, restoring healthy homeostasis in cells. Our successful track record is proven by the consolidation of the largest pipeline to date exclusively focused on disordered proteins. Our technological platform has successfully delivered five drug candidates, with IDP-121 at clinical stage to treat  multiple myeloma patients.

Differential strategy

IDP Pharma tackles human diseases by delivering drugs that directly inhibit IDP proteins master regulators, master regulators of the initiation and progression of multiple diseases. Other technologies address the pathways that lead to the activation of IDPs (upstream intervention) or the pathways activated by the IDP itself (downstream intervention). As there are multiple pathways that activate an IDP and multiple pathways activated by one IDP, no drug can block them all, making such strategies ineffective or partially effective.

For the case of multiple myeloma, IDP-121 direct inhibiton of the key protein trigeering the appearance of the diesase represents an unprecedent strategy to provide a resolutive treatment for an incurable cancer.

Intellectual property (IP)

IDP Pharma owns five first-in-class products protected by eight composition of matter patents (highest level of protection), with four patents already granted at international level (Europe, USA, China, etc).

Products and partnerships

The company´s pipeline focuses on incurable cancers, with five first in class products targeting multiple myeloma, lung cancer, small cell lung cancer, breast cancer, and glioblastoma, among others. Current licenses and partnerings include development by third parties of IDP products in ophthalmological, respiratory and dermatological disorders.

In 2023 the company consolidated its position by reaching three fundamental milestones:

• Innovation: Our first drug candidate, IDP-121, reached clinical stage of development, bringing forward a long-awaited therapy in cancer.
• Industry validation: A co-development program with a pharma company for respiratory diseases is ongoing.
• Market traction: A license option was signed with a USA Biotech for ophthalmological diseases.

Our mission is to transform the treatment of incurable cancers, forever.